Probing Androgen Receptor Signaling in Circulating Tumor Cells in Prostate Cancer
Annual summary rept. 1 July 2013 - 30 June 2014
MASSACHUSETTS GENERAL HOSPITAL BOSTON
Pagination or Media Count:
This Physician Research Training Award supports a mentored training program integrated with a research project focused on the study of circulating tumor cells CTCs in prostate cancer patients using a novel microfluidic CTC-chip . During this award, we have successfully developed a quantitative immunofluorescence assay to measure AR activity in single CTCs, and have piloted this assay in men with metastatic prostate cancer receiving treatment with hormonal therapy. We have shown that this novel assay can effectively measure AR activity levels in CTCs, and that CTC AR activity at baseline and after therapy may be correlated with treatment outcomes in prostate cancer. In addition, we have made progress in single CTC digital gene expression profiling to better understand heterogeneity of metastatic precursor cells, and have identified differences in transcriptional profiles in castration-resistant prostate cancer cells that have acquired resistance to AR targeting therapies. Finally, this Award has enabled the protection of time for research and mentored training of the PI to continue his development towards a productive career in translational prostate cancer research.
- Medicine and Medical Research